Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Locked up shares" not looking so locked up. Only the converted "locked up" shares could be sold at these prices for equal money or profit. Volume is good, but it slamming the bid is not the kind of volume increase we necessarily want. Let's hope they are slamming the bid to pick up stop losses. Would be a good time for the company to speak on their operations and plans.....
With no news following a successful roll out and completion of the IPO, and the lack of interest from the investing community that is natural for a little known company, it would have been important to have some PRs on deck about strategic partnerships, how they plan to execute a corporate plan to get value for their shareholders from operations, and lay out cliff notes on what they do. A cookie cutter COO interview with no numbers or revenue projections is not going to get any attention or price movement. If they continue their silence with shares converted at $5.60, $5s is very possible in the near term. And if they string out their silence and remain under the radar for 30 days, shorts will take over the price action. GLTA
Thanks
With the latest 8k, looks like the OS has more than doubled. Trying to read through the filing, but yet to find dates the new shares can be traded. Anyone able to point to the page where it states they are not able to be dumped right away? The $5.60 conversion price makes $7 an instant win and hope they are unable to sell yet and drive the stock down.
Agreed, a lot of potential here near and long term. I was hoping to hear more out of them over the last few months regarding their potential LNP infringement case with MRNA but they are mum about it. I have sold out to lock in nice profits and will buy once there is movement on that front.
Their Hep program looks good, but I was liking it more as a double threat with Hep and MRNA royalty play.
GLTA
Congrats to all longs. Finally seeing some nice action.
Remdesevir has FDA approval! Check your facts before spamming another board for a different play.
With as many doses that have been produced and ordered by the world by Gilead's extensive production network, it will take years for your B to ramp up and see meaningful revenue results when comparing the 2.
Having said that, I am a buyer of I*** based on Ph 2 results which have not been announced to have started yet, only plans to start. Initial dosing would be something to put out and that was supposed to have happened last week.
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19
Panic selling by scared money adding to further short positions being taken holding off the buying pressure occurring. Big blocks being thrown on both sides. Shame that several brokerage firms have limits on how many some can buy thus limiting buying power. Added more at these levels.
Whether it be due to a short squeeze or pure momo play, prices down here is a nice place to load and ride. Big hedge funds also play momo and this stock being all over the place (news, various boards, chats, etc.) has a lot of eyes and people looking to cash in on the swings. A lot of life left in this IMO. Going to be a wild ride no doubt one way or the other. Never invest more than can afford to lose= less stress.
GLTA
Interesting short info on AMC. They really adding to their short position?
https://fintel.io/ss/us/amc
The article says it all with regards to short position in AMC and the serious potential for a squeeze. In time, they will need to buy to cover their positions. The sooner they do, the less the financial pain. Will only get harder to keep it down as buying and upward pressure puts the screws to them. 3rd most shorted stock!
https://www.thestreet.com/investing/top-stocks-being-shorted-by-short-interest-gamestop-gogo
Just modified order again and put buy at limit $15, filled right away at $14.05. Glad to be a part of the squeeze now!
I tried that at $1 higher than market after the first 10 minutes and then switched back to market. Guess they need more servers LOL
I have had a buy at market order open for the last 40 minutes using Etrade that has yet to fill. Guessing shares are hard to come by. GLTA
What is the manufacturing capabilities of B for 2021 assuming it gets approval? Has the company provided guidance on doses they would be able to supply if given the green light for distribution? Are there any relationships with manufacturers already established or has everything that is being used to test been made in house and they will need to seek a deal if/ when the time comes?
TIA
Snagged some more on this dip. Have some for flipping and some for the ripping. GLTA
No mention of ANY of their royalties specifically. We know they have a couple of drugs they are receiving royalties from beyond the potential ones from MRNA and the new deals signed by Genevant in the last month.
Undeniable that ABUS is severely undervalued at this trading point. With $123 million in cash, cash equivalents, and investments= means we are trading at only 3x ratio. Crazy cheap at this price. Fins coming out in March will provide more detail as to where all the money and sources of revenue are.
No brainer at these levels IMO.
Agreed! Doubled my position during the EOY sell off at the discounted prices being offered. $5-$6 is easy in the next month or two IMO. Especially with any additional Hep B news and progress. MRNA deal or info regarding action sets it off and gives us a pop to $9 again IMO. Looking forward to Monday and getting trading started for the new year.
One has to wonder if the company is silent on anything and everything that could be a catalyst for the stock price (latest is the Genevant deal with Providence that uses ABUS technology) is a strategy for something greater or ignorance on management's part to release info on events that investors would be interested in knowing without having to sift through the internet to find different deals and uses of their technology.
Hoping it is strategy.....
Scroll down to Providence Therapeutics to learn more about their Covid-19 vaccine candidate. The most interesting part for me is:
The mRNA sequence, which is manufactured at Providence's Toronto plant, will be packaged in microscopic containers called lipid nanoparticles (LNPs) for injection into the body. The LNPs are made by Vancouver-based Genevant and are already used in an approved mRNA-based medication.
https://www.cbc.ca/news/technology/canadian-vaccine-candidates-covid-coronavirus-1.5764874
With Genevant using ABUS LNP patented technology in a deal with Providence Theraputics for a Canadian Covid-19 vaccine going into Ph. 1 trials, wonder if we get a PR this week. Canadian Government helping fund the effort is a nice bonus to ensure the testing will progress and won't stall due to lack of funding.
https://www.providencetherapeutics.com/providence-therapeutics-confirms-government-of-canada-will-support-its-phase-1-clinical-trials-for-a-covid-19-vaccine
With Moderna's vaccine getting FDA approval late Friday and seeing the quick jump at the end of AH trading, lets hope we see a continuation and maybe some news Monday.
Beautiful move on high volume!
Is there any impact or potential price increase as a result of ABUS being added to the Nasdaq Biotech index? Am seeing it being announced on Twitter, but not sure if it has any relevancy as they were already a Biotech company. Thoughts or experience in the past in a similar scenario?
Shows they have been added and states that it is used to track the performance of the same type of companies. Being a part of the index only furthers their legitimacy in the space IMO.
https://www.globenewswire.com/news-release/2020/12/12/2144097/0/en/Annual-Changes-to-the-Nasdaq-Biotechnology-Index.html
Almost time for the next leg up. Strong HBV results continue to be announced. Patented technology being used by 1 or more Covid-19 vaccines being rolled out. What more could an investor ask for when putting money into a young biotech company? Minimal downside, huge upside. The MC of ABUS should be 1B mininum and that would put us a double from here. Still holding and adding on dips. Hoping for a major market adjustment soon to reflect ABUS true valuation.
Heck of a day and bulls won the battle at 4.54. Looking great as we continue to make steady gains without any major breakout catalyst news. MRNA numbers are staggering for sales in 2021= 500 million to 1 billion vaccine doses. 2% royalties on that alone is worth more than ABUS market cap. I am seeing a buyout more than a royalty and licensing deal. Makes more sense financially for Moderna IMO. Do an all cash buyout and protect the complete Moderna pipeline to include their Covid 19 vaccine. As soon as they sell their first dose, damages are a part of the lawsuit by ABUS or Genevant. Why spend all that money on lawyers and time litigating when ABUS can still be bought cheap?
Nice action today with heavy volume and the trend is definitely our friend. Finally ABUS getting respect and more eyes are taking notice. Congrats to all longs. Have a good weekend.
That would blow things wide open if it came on the heels of this latest Ph1 trials update. Going into Ph2 is big.
Good day and broke the stubborn $3.50 mark. Hope to see continuation tomorrow.
Sadly politics even affect companies doing what they can to help solve a worldwide issue. Locked and loaded and looking for decent returns in the near term.
Trading down after beating market expectations and future Remdesevir sales going to increase given the current worldwide spike of Covid cases. Shake and bake I guess.
Good earnings report and the Remdesivir sales are going to get a lot bigger as this quarter only captured sales made mostly to the US. Looks like games are being played with the price now rather than fundamental trading.
I would guess shorts taking a position in anticipation of what could be less than expected earnings. Need to think to next quarter when the purchase order from the EU is executed and is on the books. Although I do expect earnings to meet expectations.
Lose FDA approval? Guess anything can happen. But until then, the confidence is high in it's results in treating Covid-19 by completing multiple peer reviewed studies and publishing, and the double blind placebo results that led to the FDA approval. Until such time as your less than honest take becomes realized, the EU and USA are making large purchases of the product to treat the increasing patients that are unfortunately coming down with Coronavirus. Glad we have something tested and proves affective in treating the virus. Even when something better does come along, it will have to go through many months of testing, reviews, and be granted approval for use. Until then, GILD is the first to market and will have bountiful gains in the near term. We have not even discussed the fact that they have a whole portfolio of other drugs and treatments for other diseases and viruses. This isn't a penny stock or one trick pony.
GLTA
ONLY PROVEN FDA APPROVED THERAPUETIC FOR THE ONGOING WORLDWIDE PANDEMIC! And now with a supply chain that can keep up with demand, Covid cases spiking going into the winter months, should be a lot of money to be made in the quarters to come. I expect earnings guidance to be adjusted and a higher P/E ratio which will be easily justified. Good for the world knowing we have a safe and affective therapeutic. Good for the the shareholders to benefit from this breakthrough. GLTA!
Guess a double blind placebo test and FDA approval trumps a lazily thrown together WHO report that isn't even peer reviewed. Now come the rest of the nations to follow suit over the coming weeks to approve as the FDA usually leads the pack. Hope to break 70 tomorrow and prime for what should be a good earnings report next week.
With several other studies conducted on Remdesevir, peer reviewed, results published, and analyzed by additional professionals in the field, I do not put much weight in the WHO results. If the President of the United States receives a course of it who has the best medical guidance and Dr.'s this country has to offer, I go with that over a study that pooled data from less technically advanced countries and whose professionals may not be as well trained or experienced. Not a knock on them, rather I prefer to look at the bigger picture and give less weight to the outlier report. And without trying to get political, not sure WHO is a body that can be blindly trusted at this stage as they have shown incompetentce and negligence throughout this pandemic.
Earnings should be good with all the purchases of Remdesevir by the US, EU, and other countries as it is one of only a few therapeutics that has proven efficacy in treating Covid-19.
My 2 cents. Holding strong and will watch how it plays out. Good thing Remdesevir is not Gilead's only drug that supports a much higher PPS from these levels.
Good consolidation and base forming in the $3s. Almost time for the next leg up.
And also have the President and CEO buying 70k shares on 9/23 along with their head of R&D. Seems to be same day as the MRNA filing came out. Not sure if it is coincidence, but they must like their chances and see these prices as a deal.
https://insideri.com/1447028_000144702820000143_0001447028-20-000143
ABUS insider buying 50k shares while MRNA insiders selling. Liking ABUS more and more, just requiring a lot of patience.